These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 37492565)

  • 41. JAK-STAT signaling as an ARDS therapeutic target: Status and future trends.
    Zhang Y; Gao Z; Jiang F; Yan H; Yang B; He Q; Luo P; Xu Z; Yang X
    Biochem Pharmacol; 2023 Feb; 208():115382. PubMed ID: 36528067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The JAK-STAT Signaling Pathway in Epilepsy.
    Sun H; Ma D; Cheng Y; Li J; Zhang W; Jiang T; Li Z; Li X; Meng H
    Curr Neuropharmacol; 2023; 21(10):2049-2069. PubMed ID: 36518035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
    Lensing M; Jabbari A
    Front Immunol; 2022; 13():955035. PubMed ID: 36110853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. JAK inhibitors and autoimmune rheumatic diseases.
    Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
    Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
    McInnes IB; Szekanecz Z; McGonagle D; Maksymowych WP; Pfeil A; Lippe R; Song IH; Lertratanakul A; Sornasse T; Biljan A; Deodhar A
    Rheumatology (Oxford); 2022 May; 61(5):1783-1794. PubMed ID: 34668515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of JAK/STAT Signaling Pathway and Its Downstream Influencing Factors in the Treatment of Atherosclerosis.
    Zhang X; Chen S; Yin G; Liang P; Feng Y; Yu W; Meng D; Liu H; Zhang F
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484241248046. PubMed ID: 38656132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
    Qi F; Liu F; Gao L
    Front Immunol; 2021; 12():790125. PubMed ID: 34868078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review.
    Su F; Wang T; Qin Q; Xie Z
    J Dermatolog Treat; 2024 Dec; 35(1):2302394. PubMed ID: 38263708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
    Muddebihal A; Khurana A; Sardana K
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autoimmune bullous dermatoses.
    Holtsche MM; Boch K; Schmidt E
    J Dtsch Dermatol Ges; 2023 Apr; 21(4):405-412. PubMed ID: 37070500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. JAK Inhibitors in Cytokine Storm Syndromes.
    Keenan C; Albeituni S; Nichols KE; Hines M
    Adv Exp Med Biol; 2024; 1448():583-600. PubMed ID: 39117841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
    Kahn J; Deverapalli SC; Rosmarin D
    Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
    Hammitzsch A; Lorenz G; Moog P
    Front Immunol; 2020; 11():591176. PubMed ID: 33193430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases.
    Godoi MA; Camilli AC; Gonzales KGA; Costa VB; Papathanasiou E; Leite FRM; Guimarães-Stabili MR
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. JAK Inhibitors: A New Weapon in the Skin Care Providers' Arsenal.
    Aihie O; Dyer JA
    Mo Med; 2023; 120(1):45-48. PubMed ID: 36860609
    [TBL] [Abstract][Full Text] [Related]  

  • 58. JAK/STAT defects and immune dysregulation, and guiding therapeutic choices.
    Chaimowitz NS; Smith MR; Forbes Satter LR
    Immunol Rev; 2024 Mar; 322(1):311-328. PubMed ID: 38306168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and clinical application of small-molecule inhibitors of Janus kinase.
    Zhang JY; Sun JF; Nie P; Herdewijn P; Wang YT
    Eur J Med Chem; 2023 Dec; 261():115848. PubMed ID: 37793326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Jakinibs in systemic lupus erythematosus: progress and prospects.
    Mok CC
    Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.